Browse the corpus

Walk the evidence base by book and chapter — the raw source passages that ground Ask, Differential, and the rest.

• A 2-year randomized trial of pitavastatin calcium vs placebo to treat combined dyslipidemia in adolescents with overweight and obesity1 passage
• Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study1 passage
• Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a)1 passage
• Effects of morning vs evening statin administration on lipid profile: A systematic review and meta-analysis1 passage
• Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial1 passage
• Efficacy for LDL-C-lowering and safety of pemafibrate extended-release formulation in patients with statin-intolerant hypercholesterolemia: A phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel-group trial1 passage
• Efficacy of evinacumab in patients with severe hypertriglyceridemia and a history of severe hypertriglyceridemia-related acute pancreatitis: A phase 2b trial1 passage
• Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients1 passage
• Reduction of cardiovascular events with the use of lipid-lowering medication in patients with familial hypercholesterolemia or severe primary hypercholesterolemia: A systematic review1 passage
• Safety of bempedoic acid in patients at high cardiovascular risk and with statin intolerance1 passage
• Under-reporting and under-representation of non-Hispanic Black subjects in lipid-lowering atherosclerotic cardiovascular disease outcomes trials: A systematic review1 passage